Financials data is unavailable for this security.
View more
Year on year Sun Pharmaceutical Industries Ltd grew revenues 8.42% from 484.97bn to 525.78bn. In addition the company has reduced the cost of goods sold as a percent of sales, selling, general and administrative expenses as a percent of sales and interest paid as a percent of sales. These improvements contributed to 14.12% net income growth from 95.76bn to 109.29bn.
| Gross margin | 79.97% |
|---|---|
| Net profit margin | 18.62% |
| Operating margin | 20.94% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in INRView more
In 2025, Sun Pharmaceutical Industries Ltd increased its cash reserves by 10.59%, or 9.83bn. The company earned 140.72bn from its operations for a Cash Flow Margin of 26.76%. In addition the company used 53.06bn on investing activities and also paid 79.06bn in financing cash flows.
| Cash flow per share | 55.83 |
|---|---|
| Price/Cash flow per share | 30.44 |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
Growth rates in INR
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 18.52% and 14.12%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth is above the industry average relative to its peers, while earnings per share growth is in-line with the industry average.
| Div yield(5 year avg) | 1.00% |
|---|---|
| Div growth rate (5 year) | 31.95% |
| Payout ratio (TTM) | 12.58% |
| EPS growth(5 years) | 23.76 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -8.43 |
More ▼
